Oppenheimer assumed coverage of Alpine Immune Sciences with an Outperform rating and $14 price target. There was no change to the firm’s estimates or price target, and Oppenheimer’s rating remains intact.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ALPN: